MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Estimates By $0.08 EPS

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its quarterly earnings results on Monday. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.08, FiscalAI reports.

MoonLake Immunotherapeutics Stock Performance

Shares of NASDAQ:MLTX opened at $17.33 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.60 and a current ratio of 8.60. The firm has a market cap of $1.28 billion, a PE ratio of -4.48 and a beta of 1.06. The firm’s 50 day simple moving average is $19.02 and its 200-day simple moving average is $17.89. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75.

More MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Phase 3 PsA trial met all main goals. MoonLake reported positive Week 16 results from the IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis. The 60 mg dose with induction produced an ACR50 response in 42.1% of patients, while ACR20 reached 66.5%, minimal disease activity reached 41.2%, and PASI90 reached 61% among patients with skin involvement. The results support sonelokimab’s potential as a treatment for both joint and skin symptoms. Reuters article
• Positive Sentiment: Financial position supports continued development. MoonLake ended the second quarter with $537 million in cash, cash equivalents and short-term investments, expects its cash runway to extend through mid-2028, and said up to $400 million remains available under its Hercules Capital facility. Upcoming catalysts include a planned hidradenitis suppurativa biologics-license application by the end of September and completion of IZAR-2 enrollment in the third quarter. Quiver Quantitative article
• Positive Sentiment: Quarterly loss was narrower than expected. MoonLake reported an adjusted loss of $0.84 per share, better than the $0.92 analyst consensus, although it still posted a $61.8 million net loss. Yahoo Finance article
• Neutral Sentiment: Unusually high call-option activity, with 2,707 calls purchased versus typical daily volume of 1,118, signals increased speculative interest but does not guarantee sustained buying.
• Negative Sentiment: MoonLake remains an unprofitable clinical-stage biotechnology company, with substantial research spending and no approved commercial product. Investors may also be taking profits after the trial announcement, while a “Hold” consensus rating limits the benefit of the positive data.
• Negative Sentiment: Reported insider activity shows executives made no purchases and sold shares in the past six months, potentially weighing on sentiment and reinforcing concerns about valuation.

Analyst Ratings Changes

Several equities analysts have commented on MLTX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Friday. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of MoonLake Immunotherapeutics in a research report on Monday, July 20th. Needham & Company LLC raised their price objective on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Leerink Partners increased their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Finally, BTIG Research restated a “buy” rating and issued a $30.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $24.21.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other news, CEO Da Silva Jorge Santos sold 68,289 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the transaction, the chief executive officer directly owned 2,774,893 shares in the company, valued at approximately $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $20.02, for a total value of $1,001,000.00. Following the completion of the transaction, the insider owned 2,714,746 shares in the company, valued at $54,349,214.92. This represents a 1.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 344,800 shares of company stock valued at $6,820,071 over the last quarter. Company insiders own 10.40% of the company’s stock.

Institutional Trading of MoonLake Immunotherapeutics

Institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter valued at $147,000. Virtu Financial LLC acquired a new position in MoonLake Immunotherapeutics during the 4th quarter valued at about $166,000. T. Rowe Price Investment Management Inc. acquired a new position in MoonLake Immunotherapeutics during the 4th quarter valued at about $47,000. Vident Advisory LLC purchased a new stake in MoonLake Immunotherapeutics in the fourth quarter valued at about $204,000. Finally, Virtus Investment Advisers LLC raised its position in shares of MoonLake Immunotherapeutics by 595.8% in the 4th quarter. Virtus Investment Advisers LLC now owns 17,987 shares of the company’s stock valued at $237,000 after purchasing an additional 15,402 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.